Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Genitourinary 2Dermatologic 2Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Renal Cell 16Prostatic Neoplasms 10Clear-cell metastatic renal cell carcinoma 7Urinary Bladder Neoplasms 3Urethral Neoplasms 3Neoplasm Metastasis 3Carcinoma, Transitional Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Seminoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Penile Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vulvar Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Teratoma, Testicular 1

Interventions

pembrolizumab 26Magnetic Resonance Spectroscopy 14Nivolumab 13Docetaxel 13Specimen Handling 11Radiotherapy 9Paclitaxel 9Radiosurgery 8Early Intervention, Educational 8Cyclophosphamide 8Gemcitabine 7atezolizumab 6Taxes 6Surveys and Questionnaires 6Standard of Care 6Psychiatric Rehabilitation 6Ipilimumab 6Carboplatin 6sargramostim 5Pemetrexed 5Methods 5motexafin gadolinium 4fludarabine 4X-Rays 4Interviews as Topic 4Immunoglobulin G 4Fluorouracil 4Educational Status 4Cisplatin 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × CTLA-4 Antigen × Genitourinary × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡